Free Trial
→ The Social Security Changes No One’s Talking About (From Altimetry) (Ad)
NYSE:RFL

Rafael 6/13/2023 Earnings Report

Rafael logo
$1.43 +0.03 (+2.14%)
Closing price 05/30/2025 03:58 PM Eastern
Extended Trading
$1.42 0.00 (-0.35%)
As of 05/30/2025 06:41 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
ProfileEarnings History

Rafael EPS Results

Actual EPS
-$0.06
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Rafael Revenue Results

Actual Revenue
$0.07 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Rafael Announcement Details

Quarter
Date
6/13/2023
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Rafael's Q3 2025 earnings is scheduled for Friday, June 13, 2025, with a conference call scheduled on Tuesday, June 10, 2025 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Rafael Earnings Headlines

Facing Braves, Boston’s Rafael Devers looks to end May with a bang
June 1 at 8:11 AM | msn.com
Red Sox-Rafael Devers Drama Gets Likely Final Twist Of 2025
May 31 at 9:29 PM | msn.com
Trump Knows Exactly What He's Doing
REVEALED: $194 Trillion Trump Market Pattern Trump fires off a tweet and stocks tank… He gives a speech and the markets soar… Now, a new Trump executive order is set to set off a wave worth a potential $194 trillion in the markets. And Wall Street insider Larry Benedict says it could hand investors who missed out on Trump’s first term a second chance.
June 1, 2025 | Brownstone Research (Ad)
Red Sox’s Craig Breslow reveals insight on Rafael Devers first base conversations
May 31 at 9:29 PM | msn.com
Red Sox reportedly not expecting Rafael Devers to play defense in 2025
May 31 at 3:43 AM | msn.com
Red Sox make Rafael Devers fielding decision after long controversy
May 30 at 10:42 PM | msn.com
See More Rafael Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Rafael? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Rafael and other key companies, straight to your email.

About Rafael

Rafael (NYSE:RFL) primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. It operates in two segments, Healthcare and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Its lead drug candidate is CPI-613 (devimistat), currently under Phase III clinical study for the treatment of metastatic pancreatic cancer and acute myeloid leukemia. The company is also involved in developing Promitil, a molecule designed for the targeted delivery of mitomycin-C in a proprietary prodrug form, completed Phase 1B clinical studies; Folate-targeted Promitil (Promi-Fol) which is aimed at local treatment (intravesical) of superficial bladder cancer; and Promi-Dox, a highly potent dual drug liposome with MLP and doxorubicin targeting a potential basket of tumors. In addition, it engages in the development of surgical and procedural devices, including orthopedic arthroscopy instrumentation. Rafael Holdings, Inc. was incorporated in 2017 and is headquartered in Newark, New Jersey.

View Rafael Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles